ADMA Biologics Inc vs United States Oil ETF — how do they compare? ADMA Biologics Inc trades at $9.84 (market cap $2.22B), while United States Oil ETF trades at $127.23. The key difference: United States Oil ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | USO | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $152.96 |
52-Week Low | $7.60 | $66.17 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
USO trades at $127.36, up 1.14% with bullish technical signals from moving averages. The stock faces mixed sentiment as oil markets balance supply disruptions from Middle East tensions against OPEC's downward demand revisions. Technical indicators show strong momentum with ADX signaling trend strength while RSI remains neutral, suggesting room for further movement.
The outlook remains volatile with geopolitical risks driving price action. Upside potential exists if Middle East supply constraints persist, but demand destruction concerns and inventory builds present headwinds. Investors should monitor Strait of Hormuz developments and EIA inventory data for directional catalysts.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →